

In vitro evaluation of antiviral activity of single and combination of natural products against SARS-CoV-2

Antiviral Research

181, 104878

DOI: [10.1016/j.antiviral.2020.104878](https://doi.org/10.1016/j.antiviral.2020.104878)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). <i>EClinicalMedicine</i> , 2020, 28, 100591.	3.2	74
2	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1048.	3.8	1,032
3	In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2. <i>Molecules</i> , 2020, 25, 5064.	1.7	63
4	Insights into the biomarkers of viral encephalitis from clinical patients. <i>Pathogens and Disease</i> , 2021, 79, .	0.8	3
5	COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus. <i>International Immunopharmacology</i> , 2021, 90, 107220.	1.7	18
6	Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 137-144.	1.0	12
7	Different Versions of Atom-Bond Connectivity Indices of Some Molecular Structures: Applied for the Treatment and Prevention of COVID-19. <i>Polycyclic Aromatic Compounds</i> , 2022, 42, 3748-3761.	1.4	6
8	Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1322, 195-218.	0.8	5
9	The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV. <i>Archives of Virology</i> , 2021, 166, 675-696.	0.9	66
10	Virucidal and Antiviral Activity of Astodrimer Sodium against SARS-CoV-2 in Vitro. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
11	Mapping major SARS-CoV-2 drug targets and assessment of druggability using computational fragment screening: Identification of an allosteric small-molecule binding site on the Nsp13 helicase. <i>PLoS ONE</i> , 2021, 16, e0246181.	1.1	15
12	Berberine and Obatoclox Inhibit SARS-Cov-2 Replication in Primary Human Nasal Epithelial Cells In Vitro. <i>Viruses</i> , 2021, 13, 282.	1.5	50
13	Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, 25-53.	4.2	20
14	Exploring the active constituents of <i>Oroxylum indicum</i> in intervention of novel coronavirus (COVID-19) based on molecular docking method. <i>Network Modeling Analysis in Health Informatics and Bioinformatics</i> , 2021, 10, 8.	1.2	15
15	SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 325-337.	2.4	84
16	5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro. <i>Biochemical and Biophysical Research Communications</i> , 2021, 545, 203-207.	1.0	29
18	A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study. <i>FASEB Journal</i> , 2021, 35, e21360.	0.2	40
19	In Silico Evaluation of Cyclophilin Inhibitors as Potential Treatment for SARS-CoV-2. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab189.	0.4	5

#	ARTICLE	IF	CITATIONS
20	Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. <i>IScience</i> , 2021, 24, 102367.	1.9	126
21	Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4067.	1.8	27
22	Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus. <i>Molecules</i> , 2021, 26, 2593.	1.7	29
24	A Convenient and Biosafe Replicon with Accessory Genes of SARS-CoV-2 and Its Potential Application in Antiviral Drug Discovery. <i>Virologica Sinica</i> , 2021, 36, 913-923.	1.2	25
25	A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis. <i>International Journal of Infectious Diseases</i> , 2021, 106, 71-77.	1.5	32
26	Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro. <i>Nanomedicine</i> , 2021, 16, 1187-1202.	1.7	58
27	Simple rapid in vitro screening method for SARS-CoV-2 anti-virals that identifies potential cytotoxicity-associated false positives. <i>Virology Journal</i> , 2021, 18, 123.	1.4	21
28	Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0009721.	1.4	58
29	Virucidal and antiviral activity of astodimer sodium against SARS-CoV-2 in vitro. <i>Antiviral Research</i> , 2021, 191, 105089.	1.9	24
30	Effectiveness of favipiravir in COVID-19: a live systematic review. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2575-2583.	1.3	43
31	A bird's eye view on a therapeutically "wonder molecule": Berberine. <i>Phytomedicine Plus</i> , 2021, 1, 100070.	0.9	17
32	Remdesivir and Cyclosporine Synergistically Inhibit the Human Coronaviruses OC43 and SARS-CoV-2. <i>Frontiers in Pharmacology</i> , 2021, 12, 706901.	1.6	16
33	Low rotational barriers for the most dynamically active methyl groups in the proposed antiviral drugs for treatment of SARS-CoV-2, apilimod and tetrandrine. <i>Chemical Physics Letters</i> , 2021, 777, 138727.	1.2	9
34	Model-Informed Repurposing of Medicines for SARS-CoV-2: Extrapolation of Antiviral Activity and Dose Rationale for Paediatric Patients. <i>Pharmaceutics</i> , 2021, 13, 1299.	2.0	3
35	Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?. <i>Frontiers in Medicine</i> , 2021, 8, 663708.	1.2	13
36	Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to bedside. <i>Infection, Genetics and Evolution</i> , 2021, 93, 104944.	1.0	9
38	Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets. <i>Molecules</i> , 2021, 26, 632.	1.7	22
39	Topological indices and QSPR/QSAR analysis of some antiviral drugs being investigated for the treatment of COVID-19 patients. <i>International Journal of Quantum Chemistry</i> , 2021, 121, e26594.	1.0	78

#	ARTICLE	IF	CITATIONS
40	Natural history of COVID-19 and therapeutic options. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1159-1184.	1.3	101
48	A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. <i>EMBO Molecular Medicine</i> , 2021, 13, e13105.	3.3	62
49	Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. <i>EMBO Molecular Medicine</i> , 2021, 13, e13426.	3.3	87
50	Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. <i>Current Molecular Medicine</i> , 2022, 22, 621-639.	0.6	2
51	The Impact of SARS-CoV-2 Infection, and Application of Immunosuppressive Agents in Kidney Transplant Recipients Suffering from COVID-19. <i>Pharmaceuticals</i> , 2021, 14, 1054.	1.7	5
52	Targeting autophagy with natural products to prevent SARS-CoV-2 infection. <i>Journal of Traditional and Complementary Medicine</i> , 2022, 12, 55-68.	1.5	14
53	COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks. <i>International Journal of Biological Macromolecules</i> , 2021, , .	3.6	14
54	Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection. <i>Nature Communications</i> , 2021, 12, 5809.	5.8	37
55	Immunopathological events surrounding IL-6 and IFN- λ : A bridge for anti-lupus erythematosus drugs used to treat COVID-19. <i>International Immunopharmacology</i> , 2021, 101, 108254.	1.7	2
56	Phytochemicals for the treatment of COVID-19. <i>Journal of Microbiology</i> , 2021, 59, 959-977.	1.3	19
58	Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab ϵ) ₂ fragment derived from equine polyclonal antibodies. <i>Toxicology and Applied Pharmacology</i> , 2022, 434, 115796.	1.3	3
59	Evaluating cepharanthine analogues as natural drugs against SARS-CoV-2. <i>FEBS Open Bio</i> , 2022, 12, 285-294.	1.0	20
60	Treatments for COVID-19: Lessons from 2020 and new therapeutic options. <i>Current Opinion in Pharmacology</i> , 2022, 62, 43-59.	1.7	23
61	The Potential Use of Cyclosporine Ultrafine Solution Pressurised Metered-Dose Inhaler in the Treatment of COVID-19 Patients. <i>Recent Advances in Drug Delivery and Formulation</i> , 2021, 15, .	0.3	0
62	Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. <i>Future Microbiology</i> , 2021, 16, 1341-1370.	1.0	25
63	A new screening system for entry inhibitors based on cell-to-cell transmitted syncytia formation mediated by self-propagating hybrid VEEV-SARS-CoV-2 replicon. <i>Emerging Microbes and Infections</i> , 2022, 11, 465-476.	3.0	4
64	Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106542.	1.1	7
65	Advances and gaps in SARS-CoV-2 infection models. <i>PLoS Pathogens</i> , 2022, 18, e1010161.	2.1	61

#	ARTICLE	IF	CITATIONS
66	Molecular docking of phytochemical compounds of Momordica charantia as potential inhibitor against SARS-CoV-2. Infectious Disorders - Drug Targets, 2022, 22, .	0.4	0
67	Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences. , 2022, 235, 108121.		20
68	Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. MBio, 2021, 12, e0334721.	1.8	45
69	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. Pathogens, 2022, 11, 275.	1.2	9
70	Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening. Antiviral Research, 2022, 199, 105268.	1.9	15
71	Multiscale Model of Antiviral Timing, Potency, and Heterogeneity Effects on an Epithelial Tissue Patch Infected by SARS-CoV-2. Viruses, 2022, 14, 605.	1.5	8
72	The naturallyâ€derived alkaloids as a potential treatment for <scp>COVID</scp>â€19: A scoping review. Phytotherapy Research, 2022, 36, 2686-2709.	2.8	12
73	Nonâ€immunosuppressive Cyclophilin Inhibitors. Angewandte Chemie - International Edition, 2022, 61, .	7.2	12
74	Nonâ€immunosuppressive Cyclophilin Inhibitors. Angewandte Chemie, 0, , .	1.6	0
76	Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic. , 2021, , 39-68.		0
77	Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges. PLoS Pathogens, 2021, 17, e1010106.	2.1	12
78	Modeling the Structureâ€Activity Relationship of Arbidol Derivatives and Other SARS-CoV-2 Fusion Inhibitors Targeting the S2 Segment of the Spike Protein. Journal of Chemical Information and Modeling, 2021, 61, 5906-5922.	2.5	2
79	Chemicals Informatics: Explore Structural Factors and Potential Chemicals based on Public Literatures. , 2021, , .		1
80	Design, Synthesis, and Development of 4â€[(7â€Chloroquinolineâ€4â€yl)amino]phenol as a Potential SARSâ€CoVâ€2 Mpro Inhibitor. ChemistrySelect, 2022, 7, .	0.7	7
81	Erythrodermic psoriasis in post-coronavirus disease 2019 patient. Asia Pacific Allergy, 2022, 12, e16.	0.6	3
82	Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations. BMC Pharmacology & Toxicology, 2022, 23, .	1.0	8
83	No effect of remdesivir or betamethasone on upper respiratory tract SARS-CoV-2 RNA kinetics in hospitalised COVID-19 patients: a retrospective observational study. Infectious Diseases, 2022, 54, 703-712.	1.4	3
84	A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics. Expert Review of Clinical Pharmacology, 2022, 15, 945-958.	1.3	3

#	ARTICLE	IF	CITATIONS
85	Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates. <i>Nature Communications</i> , 2022, 13, .	5.8	12
86	Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-70.	0.7	13
87	The role of berberine in Covid-19: potential adjunct therapy. <i>Inflammopharmacology</i> , 2022, 30, 2003-2016.	1.9	20
88	Molecular Simulation-Driven Drug Repurposing for the Identification of Inhibitors Against Non-Structural Proteins of SARS-CoV-2. <i>Methods in Pharmacology and Toxicology</i> , 2021, , 683-713.	0.1	0
89	In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2. <i>Antiviral Research</i> , 2022, 208, 105450.	1.9	13
90	The investigation of the complex population-drug-drug interaction between ritonavir-boosted lopinavir and chloroquine or ivermectin using physiologically-based pharmacokinetic modeling. <i>Drug Metabolism and Personalized Therapy</i> , 2022, .	0.3	4
91	Antiviral effects of phytochemicals against severe acute respiratory syndrome coronavirus 2 and their mechanisms of action: A review. <i>Phytotherapy Research</i> , 2023, 37, 1036-1056.	2.8	9
92	Umifenovir Epigenetically Targets the <i>IL-10</i> Pathway in Therapy against Coxsackievirus B4 Infection. <i>Microbiology Spectrum</i> , 0, , .	1.2	0
93	Bioactivity and In Silico Studies of Isoquinoline and Related Alkaloids as Promising Antiviral Agents: An Insight. <i>Biomolecules</i> , 2023, 13, 17.	1.8	4
94	Synthesis and Molecular Docking Study of Novel Pyrimidine Derivatives against COVID-19. <i>Molecules</i> , 2023, 28, 739.	1.7	9
95	A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?. <i>Inflammopharmacology</i> , 2023, 31, 21-35.	1.9	7
96	Role of nutrition in minimizing mental and health-related issues during COVID-19: a systematic literature review. <i>Nutrition and Food Science</i> , 2023, 53, 659-699.	0.4	1
97	Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population. <i>Molecules</i> , 2023, 28, 2332.	1.7	6
98	Identification of berberine as a potential therapeutic strategy for kidney clear cell carcinoma and COVID-19 based on analysis of large-scale datasets. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
99	Repurposed Drugs Against SARS-CoV-2 Replication in COVID-19. , 2023, , 52-71.		1
100	Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. <i>European Journal of Clinical Pharmacology</i> , 2023, 79, 723-751.	0.8	7